Novartis to acquire neuroscience company Cadent Therapeutics in $770m worth deal

Novartis to acquire neuroscience company Cadent Therapeutics in $770m worth deal

Novartis acquisition of Cadent Therapeutics : Swiss pharma giant Novartis has agreed to acquire a US neuroscience company Cadent Therapeutics, in a deal worth up to $770 million. The consideration includes an upfront payment of $210 million and up to $560 million in milestone payments. Cadent Therapeutics was launched about three years ago via the […]

Biogen strikes $600m deal with Pfizer for promising schizophrenia drug

Biogen strikes $600m deal with Pfizer for promising schizophrenia drug

Biogen, a leading US biotechnology firm, has reached a significant agreement to acquire Pfizer’s neurology drug candidate, PF-04958242, which is being developed to address cognitive impairment associated with schizophrenia (CIAS). The deal, potentially worth almost $600 million, includes an upfront payment of $75 million, with additional milestone payments and royalties that could total up to […]